Clinical research of traditional chinese medical intervention on impaired glucose tolerance

American Journal of Chinese Medicine

Volumn 41, Issue 1, 2013, Pages 21-32

  Gao, Yanbin ^a,b   Zhou, Hui ^b   Zhao, Huiling ^b   Feng, Xingzhong ^c   Feng, Jianhua ^d   Li, Yi ^e   Zhang, Hong ^f   Lu, Hao ^g   Qian, Qiuhai ^d   Yu, Xiuchen ^b   Zhang, Ning ^h   Yu, Jiangyi ⁱ   Ni, Qing ^j   Pan, Mingzheng ^k  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^e BEIJING HOSPITAL   (China)

^f Beijing Fangshan Traditional Chinese Medicine Hospital   (China)

^g SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^h Wangjing Hospital of CACMS   (China)

ⁱ AFFILIATED HOSPITAL OF NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^j INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^k PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

more..

Author keywords

Clinical Research; Impaired Glucose Tolerance (IGT); Traditional Chinese Medicine (TCM)

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; INSULIN;

ADULT; AGED; ARTICLE; BODY MASS; CHINESE MEDICINE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; TREATMENT OUTCOME;

DIABETES MELLITUS, TYPE 2; DRUGS, CHINESE HERBAL; FEMALE; FOLLOW-UP STUDIES; GLUCOSE INTOLERANCE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS;

EID: 84872919483     PISSN: 0192415X     EISSN: None     Source Type: Journal    
DOI: 10.1142/S0192415X1350002X     Document Type: Article

References (33)

1. Alberti, K.G. and P.Z. Zimmet. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15: 539-553, 1998
2. Chiasson, J.L. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: The Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial. Endocr. Pract. 12(Suppl 1): 25-30, 2006
3. Chiasson, J.L., R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik and M. Laakso. Acarbose for prevention of type 2 diabetes mellitus: The STOP-NIDDM randomised trial. Lancet 359: 2072- 2077, 2002
4. Chiasson, J.L., R.G. Josse, R. Gomis, M. Hanefeld, A. Karasik and M. Laakso. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial. JAMA 290: 486-494, 2003
5. Ding, X. and H.L. Lu, History of diabetic research and assessment of published literature. In: R. Liu and J.Z. Zhao (eds.) Study of Diagnosis and Treatment of Diabetes and Diabetic Complications Based on the Traditional Chinese Medicine and Western Medicine. People's Health Publishing House, Beijing, 2009, pp. 85-97
6. DREAM Trial Investigators, H.C. Gerstein, S. Yusuf, J. Bosch, J. Pogue, P. Sheridan, N. Dinccag, M. Hanefeld, B. Hoogwerf, M. Laakso, V. Mohan, J. Shaw, B. Zinman and R.R. Holman Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial. Lancet 368: 1096-1105, 2006
7. Gong, Q., E.W. Gregg, J. Wang, Y. An, P. Zhang, W. Yang, H. Li, Y. Jiang, Y. Shuai, B. Zhang, J. Zhang, R.B. Gerzoff, G. Roglic, Y. Hu, G. Li and P.H. Bennett. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetesrelated microvascular complications: The China Da Qing Diabetes Prevention Outcome Study Diabetologia 54: 300-307, 2011
8. Haffner, S.M., E. Kennedy, C. Gonzalez, M.P. Stern and H. Miettinen. A prospective analysis of the HOMA model. The Mexico City Diabetes Study. Diabetes Care 19: 1138-1141, 1996
9. Joint Committee for Developing Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults. Chinese guidelines on prevention and treatment of dyslipidemia in adults. Zhonghua Xin Xue Guan Bing Za Zhi 35: 390-419, 2007
10. Knowler, W.C., E. Barrett-Connor, S.E. Fowler, R.F. Hamman, J.M. Lachin, E.A. Walker and D.M. Nathan. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin N. Engl. J. Med. 346: 393-403, 2002
11. Kong, W.J., H. Zhang, D.Q. Song, R. Xue, W. Zhao, J. Wei, Y.M. Wang, N. Shan, Z.X. Zhou and P. Yang. Berberine reduces insulin resistance through protein kinase C-dependent upregulation of insulin receptor expression. Metabolism 58: 109-119, 2009
12. Lee, O.H., D.H. Seo, C.S. Park and Y.C. Kim. Puerarin enhances adipocyte differentiation, adiponectin expression, and antioxidant response in 3T3-L1 cells. Biofactors 36: 459-467, 2010
13. Li, G., P. Zhang, J. Wang, E.W. Gregg, W. Yang, Q. Gong, H. Li, Y. Jiang, Y. An, Y. Shuai, B. Zhang, J. Zhang, T.J. Thompson, R.B. Gerzoff, G. Roglic, Y. Hu and P.H. Bennett. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study: A 20-year follow-up study. Lancet 371: 1783-1789, 2008
14. Meezan, E., E.M. Meezan, K. Jones, R. Moore, S. Barnes and J.K. Prasain. Contrasting effects of puerarin and daidzin on glucose homeostasis in mice. J. Agric. Food Chem. 53: 8760-8767, 2005
15. Naowaboot, J., P. Pannangpetch, V. Kukongviriyapan, A. Prawan, U. Kukongviriyapan and A. Itharat. Mulberry leaf extract stimulates glucose uptake and GLUT4 translocation in rat adipocytes Am. J. Chin. Med. 40: 163-175, 2012
16. NAVIGATOR Study Group, J.J. McMurray, R.R. Holman, S.M. Haffner, M.A. Bethel, B. Holzhauer, T.A. Hua, Y. Belenkov, M. Boolell, J.B. Buse, B.M. Buckley, A.R. Chacra, F.T. Chiang, B. Charbonnel, C.C. Chow, M.J. Davies, P. Deedwania, P. Diem, D. Einhorn, V. Fonseca, G.R. Fulcher, Z. Gaciong, S. Gaztambide, T. Giles, E. Horton, H. Ilkova, T. Jenssen, S.E. Kahn, H. Krum, M. Laakso, L.A. Leiter, N.S. Levitt, V. Mareev, F. Martinez, C. Masson, T. Mazzone, E. Meaney, R. Nesto, C. Pan, R. Prager, S.A. Raptis, G.E. Rutten, H. Sandstroem, F. Schaper, A. Scheen, O. Schmitz, I. Sinay, V. Soska, S. Stender, G. Tamas, G. Tognoni, J. Tuomilehto, A.S. Villamil, J. Vozar and R.M. Califf. Effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362: 1477-1490, 2010
17. Oh, T., D. Choi and J. Yun. Morus alba L. root bark stimulates adipocyte differentiation in 3T3-L1 cells. Biotech. Bioprocess Eng. 16: 978-986, 2011
18. Pan, X.R., G.W. Li, Y.H. Hu, J.X. Wang, W.Y. Yang, Z.X. An, Z.X. Hu, J. Lin, J.Z. Xiao, H.B. Cao, P.A. Liu, X.G. Jiang, Y.Y. Jiang, J.P. Wang, H. Zheng, H. Zhang, P.H. Bennett and B.V. Howard. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20: 537-544, 1997
19. Ramachandran, A., C. Snehalatha, S. Mary, B. Mukesh, A.D. Bhaskar and V. Vijay. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49: 289-297, 2006
20. Snehalatha, C., S. Mary, S. Selvam, C.K. Sathish Kumar, S.B. Shetty, A. Nanditha and A. Ramachandran Changes in insulin secretion and insulin sensitivity in relation to the glycemic outcomes in subjects with impaired glucose tolerance in the Indian Diabetes Prevention Programme-1 (IDPP-1). Diabetes Care 32: 1796-1801, 2009
21. Song, L.C., K.Z. Chen and J.Y. Zhu. The effect of Coptis chinensis on lipid peroxidation and antioxidases activity in rats. Zhongguo Zhong Xi Yi Jie He Za Zhi 12: 421-423, 390, 1992
22. Tong, X., Q. Ni, F. Lian, J. Hu, F. Yu, X. Ouyang, Z. Jiang, S. Wu, H. Jiang and T. Gao. Multi-center randomized controlled and double blind trial of Tang-min-ling pills in the treatment of type 2 diabetes mellitus. Chin. J. Clin. Pharm. 25: 104-108, 2009
23. Tong, X.L., L. Dong, L. Chen and Z. Zhen. Treatment of diabetes using traditional chinese medicine: past, present and future. Am. J. Chin. Med. 40: 877-886, 2012
24. Tuomilehto, J., J. Lindstrom, J.G. Eriksson, T.T. Valle, H. Hamalainen, P. Ilanne-Parikka, S. Keinanen- Kiukaanniemi, M. Laakso, A. Louheranta, M. Rastas, V. Salminen and M. Uusitupa Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N. Engl. J. Med. 344: 1343-1350, 2001
25. Wong, K.H., G.Q. Li, K.M. Li, V. Razmovski-Naumovski and K. Chan. Kudzu root: Traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases. J. Ethnopharmacol 584-607, 2011
26. Wu, M., J. Wang and L.T. Liu. Advance of studies on anti-atherosclerosis mechanism of berberine Chin. J. Integr. Med. 16: 188-192, 2010
27. Xu, M. History and current development of diabetic treatment. In: Xu, M. (ed.), Diabetes. The Science and Technology Press in Shanghai, Shanghai, 2010, pp. 9
28. Yang, W., J. Lu, J. Weng, W. Jia, L. Ji, J. Xiao, Z. Shan, J. Liu, H. Tian, Q. Ji, D. Zhu, J. Ge, L. Lin, L. Chen, X. Guo, Z. Zhao, Q. Li, Z. Zhou, G. Shan and J. He. Prevalence of diabetes among men and women in China. N. Engl. J. Med. 362: 1090-1101, 2010
29. Zhang, H., J. Wei, R. Xue, J.D. Wu, W. Zhao, Z.Z. Wang, S.K. Wang, Z.X. Zhou, D.Q. Song, Y.M. Wang, H.N. Pan, W.J. Kong and J.D. Jiang. Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59: 285-292, 2010a.
30. Zhang, M., M. Chen, H.Q. Zhang, S. Sun, B. Xia and F.H. Wu. In vivo hypoglycemic effects of phenolics from the root bark of Morus alba. Fitoterapia 80: 475-477, 2009
31. Zhang, W., C.Q. Liu, P.W. Wang, S.Y. Sun, W.J. Su, H.J. Zhang, X.J. Li and S.Y. Yang. Puerarin improves insulin resistance and modulates adipokine expression in rats fed a high-fat diet. Eur J. Pharmacol. 649: 398-402, 2010b.
32. Zhen, Z., B. Chang, M. Li, F.M. Lian, L. Chen, L. Dong, J. Wang, B. Yu, W.K. Liu, X.Y. Li, P.J. Qin, J.H. Zhang and X.L. Tong. Anti-diabetic effects of a Coptis chinensis containing new traditional Chinese medicine formula in type 2 diabetic rats. Am. J. Chin. Med. 39: 53-63, 2011
33. Zhiping, W., Jianzhong T. and Zhenlun G. Study on chemical constituents and pharmacological activities of Cortex Mori. Chinese Wild Plant Resources 5: 2004